Ravelcare IPO opens for subscription from December 1 to December 3, 2025, with a price band of ₹123 to ₹130 per share. The IPO aims to raise ₹24.10 crore and is a fresh issue, with shares expected to list on BSE SME around December 8, 2025. Ravelcare follows a direct-to-consumer (D2C) business model, selling its products through its website and leading e-commerce platforms. The Ravelcare IPO offers investors exposure to the growing health and wellness segment with a focus on expanding production and market reach.
₹50
₹130
₹
Expert Opinions
Market sentiment for Ravelcare IPO is positive, driven by growing investor interest in D2C beauty and personal care brands amid rising online penetration in India. Company strengths include a Shark Tank-backed profile, direct-to-consumer model via e-commerce platforms, and a diverse health/wellness product range targeting urban consumers. Risks involve intense competition in the fragmented BPC sector, brand building challenges, and dependency on digital marketing effectiveness.
Valuation analysis of Ravelcare IPO in 2025 reveals a Return on Equity (ROE) of 68.04%, ROCE of 68.32%, and Net Asset Value (NAV) of ₹20.68, showcasing exceptional capital efficiency and profitability. Long-term investment perspective is attractive for exposure to India’s expanding wellness market, supported by planned manufacturing expansion and marketing investments, though execution in a competitive landscape remains key.
Investor Considerations
Ravelcare IPO investors should note the company’s strong performance, with revenue growing 14% to ₹25.30 crore and profit after tax up 5% to ₹5.26 crore in FY 2025. The D2C beauty and personal care sector outlook is promising, driven by e-commerce expansion and rising urban wellness demand. Valuation analysis for Ravelcare IPO in 2025 reveals a Price to Book Value of 6.29, PAT Margin of 21.01%, and Market Capitalization of ₹89.17 Cr, indicating premium pricing with robust profitability.
Growth prospects include new manufacturing capacity in Amravati and enhanced digital marketing. Risks encompass competition, brand dependency, and execution challenges. Long-term investors stand to gain from sector tailwinds, while short-term goals warrant caution amid market volatility.
| Date | GMP | Trend |
|---|---|---|
| 01 Dec 2025 19.05 | ₹50 | Up |
| 28 Nov 2025 19.33 | ₹15 | --- |
FAQs
Ravelcare IPO Current GMP is ₹50.
Ravelcare IPO Expected Returns is 38.46%.
Ravelcare IPO estimated listing price is ₹180.